Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 154

1.

Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty.

Wade WE, Hawkins DW.

Orthopedics. 2000 Apr;23(4):335-8; discussion 338-9. Review.

PMID:
10791583
[PubMed - indexed for MEDLINE]
2.
3.

[The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].

Olsen J, Gundgaard J, Borris LC.

Ugeskr Laeger. 2005 May 23;167(21):2273-9. Danish. No abstract available.

PMID:
15962854
[PubMed - indexed for MEDLINE]
4.

Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.

Dunn CJ, Goa KL.

Pharmacoeconomics. 1996 Aug;10(2):179-90.

PMID:
10163420
[PubMed - indexed for MEDLINE]
5.

Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.

Garcia-Zozaya I.

J Ky Med Assoc. 1998 Apr;96(4):143-8.

PMID:
9577110
[PubMed - indexed for MEDLINE]
6.

Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.

Bell GK, Goldhaber SZ.

Vasc Med. 2001;6(1):23-9.

PMID:
11358156
[PubMed - indexed for MEDLINE]
7.

Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.

Haentjens P, De Groote K, Annemans L.

Arch Orthop Trauma Surg. 2004 Oct;124(8):507-17. Epub 2004 Sep 10.

PMID:
15365714
[PubMed - indexed for MEDLINE]
8.

Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.

Colwell CW Jr, Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, Hardwick ME.

J Bone Joint Surg Am. 1999 Jul;81(7):932-40.

PMID:
10428124
[PubMed - indexed for MEDLINE]
9.

Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.

O'Brien BJ, Anderson DR, Goeree R.

CMAJ. 1994 Apr 1;150(7):1083-90.

PMID:
8137188
[PubMed - indexed for MEDLINE]
Free PMC Article
10.
11.

[Venous thromboembolism prophylaxis after total hip arthroplasty].

Kučera T, Malý R, Urban K, Sponer P.

Acta Chir Orthop Traumatol Cech. 2011;78(2):101-5. Czech.

PMID:
21575551
[PubMed - indexed for MEDLINE]
12.

Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty.

Friedman RJ, Dunsworth GA.

Clin Orthop Relat Res. 2000 Jan;(370):171-82.

PMID:
10660711
[PubMed - indexed for MEDLINE]
13.

Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty.

Wade WE, Spruill WJ, Leslie RB.

Am J Orthop (Belle Mead NJ). 2003 Apr;32(4):201-5.

PMID:
12723772
[PubMed - indexed for MEDLINE]
14.

Cost analysis of ardeparin versus enoxaparin for the prophylaxis of deep vein thrombosis after knee arthroplasty.

Wade WE.

Clin Ther. 1998 Mar-Apr;20(2):347-51.

PMID:
9589825
[PubMed - indexed for MEDLINE]
15.

A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery.

Hawkins DW, Langley PC, Krueger KP.

Clin Ther. 1998 Jan-Feb;20(1):182-95.

PMID:
9522114
[PubMed - indexed for MEDLINE]
16.

Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery.

Levin LA, Bergqvist D.

Pharmacoeconomics. 2001;19(5 Pt 2):589-97. Review.

PMID:
11465303
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.

Menzin J, Colditz GA, Regan MM, Richner RE, Oster G.

Arch Intern Med. 1995 Apr 10;155(7):757-64.

PMID:
7695464
[PubMed - indexed for MEDLINE]
18.

Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery.

Saunders ME, Grant RE.

J Natl Med Assoc. 1998 Nov;90(11):677-80.

PMID:
9828582
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.

Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G; AstraZeneca Arthroplasty Study Group.

Arch Intern Med. 2001 Oct 8;161(18):2215-21.

PMID:
11575978
[PubMed - indexed for MEDLINE]
20.

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.

Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kälebo P; ODIXa-HIP Study Investigators.

J Thromb Haemost. 2006 Jan;4(1):121-8.

PMID:
16409461
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk